Brooklyn ImmunoTherapeutics (BTX) Stock Price, News & Analysis

Company Overview

Eterna Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. The company is headquartered in San Diego, CA.

Key Stats

• Today's Range: $7.61 to $7.81
• 50-Day Range: $0.25 to $7.87
• 52-Week Range: $6.66 to $8.31
• Volume: 757,664 shs
• Average Volume: 757,225 shs
• Market Capitalization: $451.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BTX Stock Analysis - Frequently Asked Questions

How have BTX shares performed this year?

Brooklyn ImmunoTherapeutics' stock was trading at $0.2940 on January 1st, 2025. Since then, BTX shares have increased by 2,508.8% and is now trading at $7.67.
View the best growth stocks for 2025 here.

How do I buy shares of Brooklyn ImmunoTherapeutics?

Shares of BTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Brooklyn ImmunoTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Brooklyn ImmunoTherapeutics investors own include Mastech Digital (MHH), Mastech Digital (MHH), Altimeter Growth Corp. 2 (AGCB), African Gold Acquisition (AGAC), Aldel Financial (ADF) and Adit EdTech Acquisition (ADEX).

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Information
• Industry: Television Broadcasting
• Sub-Industry: N/A
• Current Symbol: NYSE:BTX
• CUSIP: N/A
• CIK: 748592
• Web: N/A
• Phone: (212) 582-1199
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 58,826,000
• Free Float: N/A
• Market Cap: $451.20 million
• Optionable: No Data
• Beta: 4.61